Glaxosmithkline
Biotechnology pharmaceutical product discovery and development.
Based in DC
🤖
AI Overview
With $1.9M in lobbying spend across 33 quarterly filings, Glaxosmithkline is a significant lobbying presence. Their lobbying covers 1 issue area. Active from 2018 to 2025.
$1.9M
Total Spend
8
Years Active
1
Firms Hired
4
Lobbyists Deployed
1
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $240K |
| 2019 | $240K |
| 2020 | $240K |
| 2021 | $240K |
| 2022 | $360K |
| 2023 | $240K |
| 2024 | $240K |
| 2025 | $90K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues
- •General health care coverage and reimbursement for prescription drugs; reforms to H.R. 3590, the Patient Protection and Affordable Care Act; regulatory issues related to pandemic influenza and biodefe
- •General health care coverage and reimbursement for prescription drugs; reforms to the Patient Protection and Affordable Care Act; regulatory issues related to pandemic influenza and biodefense vaccine
- •General health care coverage and reimbursement for prescription drugs; drug pricing reform; and the Food and Drug Administration legislative and regulatory issues. The re-authorization of the Pandemic
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.